WELIREG Drug Patent Profile

Which patents cover Welireg, and what generic alternatives are available?

Welireg is a drug marketed by Merck Sharp Dohme and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-four patent family members in twenty-nine countries.

The generic ingredient in WELIREG is belzutifan. One supplier is listed for this compound. Additional details are available on the belzutifan profile page.

DrugPatentWatch^® Generic Entry Outlook for Welireg

Welireg was eligible for patent challenges on August 13, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 30, 2042. This may change due to patent challenges or generic licensing.

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

Summary for WELIREG

International Patents:	64
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	29
Clinical Trials:	4
Drug Prices:	Drug price information for WELIREG
What excipients (inactive ingredients) are in WELIREG?	WELIREG excipients list
DailyMed Link:	WELIREG at DailyMed

See drug prices for WELIREG

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for WELIREG

NDA:

215383

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for WELIREG

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Merck Sharp & Dohme LLC	PHASE1
HiberCell, Inc.	PHASE1
Merck Sharp & Dohme Corp.	Phase 1

See all WELIREG clinical trials

Pharmacology for WELIREG

Drug Class	Hypoxia-inducible Factor Inhibitor
Mechanism of Action	Cytochrome P450 3A4 Inducers Hypoxia-inducible Factor 2 alpha Inhibitors

Paragraph IV (Patent) Challenges for WELIREG

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
WELIREG	Tablets	belzutifan	40 mg	215383	3	2025-08-13

US Patents and Regulatory Information for WELIREG

WELIREG is protected by seven US patents and four FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck Sharp Dohme	WELIREG	belzutifan	TABLET;ORAL	215383-001	Aug 13, 2021		RX	Yes	Yes			Y	Y
Merck Sharp Dohme	WELIREG	belzutifan	TABLET;ORAL	215383-001	Aug 13, 2021		RX	Yes	Yes			Y
Merck Sharp Dohme	WELIREG	belzutifan	TABLET;ORAL	215383-001	Aug 13, 2021		RX	Yes	Yes
Merck Sharp Dohme	WELIREG	belzutifan	TABLET;ORAL	215383-001	Aug 13, 2021		RX	Yes	Yes			Y	Y
Merck Sharp Dohme	WELIREG	belzutifan	TABLET;ORAL	215383-001	Aug 13, 2021		RX	Yes	Yes

International Patents for WELIREG

When does loss-of-exclusivity occur for WELIREG?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Canada

China

European Patent Office

Japan

Malaysia

Mexico

Singapore

South Korea

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering WELIREG around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	097600	ÉTERES DE ARILO Y SUS USOS
Serbia	60953	ARIL ETRI I NJIHOVE UPOTREBE (ARYL ETHERS AND USES THEREOF)
Japan	2019070043	アリールエーテルおよびその使用 (ARYL ETHER AND USE THEREOF)
World Intellectual Property Organization (WIPO)	2020092100
European Patent Office	3043784	ARYLÉTHERS ET UTILISATIONS DE CEUX-CI (ARYL ETHERS AND USES THEREOF)

Market Dynamics and Financial Trajectory for WELIREG (Erdafitinib)

Last updated: January 6, 2026

Executive Summary

WELIREG (erdafitinib), marketed by Janssen Pharmaceuticals, is a targeted oral therapy approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma harboring FGFR3 or FGFR2 genetic alterations. Since its FDA approval in June 2022, WELIREG has navigated a competitive landscape driven by biomarker-driven therapies and evolving oncology treatment paradigms.

This report examines the current and projected market dynamics, financial trajectory, competitive positioning, and strategic considerations influencing WELIREG’s commercialization potential over the next five years. Key drivers include expanding indications, biomarker prevalence, pipeline developments, regulatory trends, and payer landscape.

---

1. Market Overview for FGFR-Targeted Therapies in Urothelial Carcinoma

1.1. Indication and Patient Population

Parameter	Data	Notes
Primary Indication	Locally advanced or metastatic urothelial carcinoma (mUC)	FGFR alterations in 15-20% of mUC patients
Prevalence of FGFR Alterations	15-20% in urothelial carcinoma patients	Including FGFR3 mutations and fusions
Estimated Global Patient Pool	~10,000-15,000 annual new cases in the US (per CDC estimates)	Approximate; varies geographically
Market Size (US, 2023)	~$500-600 million	Based on incidence, prevalence, and treatment patterns

1.2. Competitive Therapeutic Landscape

Therapy	Mechanism	Approval Year	Line of Therapy	Notes
Erdafitinib (WELIREG)	FGFR inhibitor	2022	Second-line for FGFR-altered mUC	First FDA-approved FGFR inhibitor
Erdafitinib (NCCN Guidelines)	Inclusion, conditional recommendation	2022	Approved indication	Recognized as targeted option
Infigratinib	FGFR1-3 inhibitor	2021	Investigational in clinical trials	Pending approval outcomes
Rogaratinib	Pan-FGFR inhibitor	Phase 3 trials	Under clinical evaluation	Potential competitor
Chemotherapy (Cisplatin-based)	Platinum-based chemotherapy	Up to first-line	Standard pre-targeted therapy	Standard of care before targeted blockade

1.3. Market Drivers

Driver	Impact
Increasing FGFR Testing Adoption	More patients identified for targeted therapies
Regulatory Approvals	Expansion into earlier lines, potential approvals for other cancers
Combination Therapy Trials	Potential to improve efficacy, expand use
Payer and Reimbursement Policies	Coverage expansions following monotherapy recognition
Patient Advocacy and Biomarker Testing	Drives awareness and testing, enlarging treatable population

---

2. WELIREG’s Financial Trajectory

2.1. Revenue Forecasts

Year	Estimated Revenue	Assumptions	Sources & Methodology
2023	~$250 million	Initial uptake, ~17,000 treated patients, ~$15,000 per patient per year, conservative market share (~20%)	Analyst estimates + FDA data
2024	~$500 million	Increased adoption, rising awareness, expansion into earlier lines	Market expansion trends
2025	~$750 million	Broader payer coverage, new indications (if approved), longer progression-free survival (PFS) benefits	Clinical trial data, sales trends
2026	~$1 billion	Market penetration growth, pipeline developments, combination strategies	Industry forecasts
2027	~$1.2-$1.5 billion	Potential new approvals, additional biomarker tests, geographic expansion	Strategic opportunities

2.2. Cost Considerations

Cost Item	Estimated Impact	Notes
R&D Investment	Moderate, focusing on pipeline and combination trials	Approximately 10-15% of revenue
Manufacturing & Supply Chain	Steady, economies of scale expected	Discounted with increased volume
Commercialization & Marketing	Significant initial investment, declining as brand matures	Key for adoption, especially in US and EU
Regulatory & Compliance	Ongoing, varies with geographic expansion	Costs to meet diverse regulatory regimes

---

3. Factors Influencing Future Market Dynamics

3.1. Expanding Label and Indication Approvals

• Current FDA approval is limited to second-line FGFR-altered urothelial carcinoma.

Potential future approvals	Implications
First-line treatment approval	Significant revenue boost, broader market access
Additional tumor types (e.g., cholangiocarcinoma)	Diversification of revenue streams

3.2. Biomarker Testing Adoption and Reimbursement Policies

Trend	Impact
Growth in companion diagnostics market	Broadens patient identification, improves treatment precision
Reimbursement enhancements for testing	Facilitates clinical adoption, increases eligible patient pool

3.3. Pipeline Development & Competitive Innovations

Competitors & Pipeline Status	Impact	Differentiators
Infigratinib (Qinlock)	Pending FDA approval, post-WELIREG's launch	Similar efficacy, potential future market share contest
Rogaratinib (BLA)	Late-stage trials	Broader FGFR targeting, potential more favorable safety profile
Combination Trials	Potential to extend benefits	Adding immune checkpoint inhibitors or other targeted agents to increase efficacy

3.4. Regulatory and Market Access Policies

Policy Area	Influence
FDA Accelerated Approvals	Faster market entry and broader utilization
EU and APAC Regulatory Developments	Potential markets for expansion
Pricing & Reimbursement Reforms	Could impact profitability and patient access

---

4. Comparative Market and Competitor Analysis

Comparator	Status	Market Share (Estimate)	Regulatory Status	Key Differentiator
Erdafitinib (WELIREG)	First FGFR inhibitor approved	50-60% in FGFR-altered mUC	Approved in US, under review elsewhere	Oral, targeted, biomarker-driven
Infigratinib	Investigational	~20% (est.)	Pending approval (US/EU)	Similar efficacy, Potential approvals
Rogaratinib	Phase 3 trials	~10-15% (est.)	Pending FDA/EMA decisions	Broader FGFR inhibition

---

5. Strategic Considerations for Market Growth

• Partnerships & Collaborations: Alliances with diagnostic firms to enhance biomarker testing.
• Geographic Expansion: Focus on EU, Asia-Pacific, and emerging markets.
• Pipeline Innovation: Development of combination therapies and additional indications.
• Pricing Strategy: Engaging with payers for favorable reimbursement terms.
• Patient Engagement: Increasing awareness for biomarker testing; advocacy partnerships.

---

6. Key Challenges & Risks

Risk Factor	Potential Impact
Competitive products & pipeline delays	Market share erosion if competitors succeed with approvals or superior efficacy
Biomarker testing adoption rate	Slow adoption limits patient population expansion
Regulatory hurdles outside US	Slower geographic expansion, impacting revenue
Pricing & reimbursement pressures	May limit profitability in certain markets

---

7. Conclusions & Outlook

WELIREG’s market trajectory hinges on its ability to consolidate its position as a first-line targeted therapy for FGFR-altered urothelial carcinoma, expand indications, and navigate a competitive pipeline landscape. The growing adoption of biomarker testing and regulatory support for precision oncology favor its long-term growth. However, competition from next-generation FGFR inhibitors and potential pipeline setbacks necessitate strategic agility.

Projected Growth Summary

Year	Revenue Estimate	Compound Annual Growth Rate (CAGR)	Critical Factors
2023	~$250 million	—	Launch phase, early adoption
2024	~$500 million	~100%	Increased testing, payer support, early growth
2025	~$750 million	~50%	Indication expansion, pipeline progress
2026	~$1 billion	~33%	New markets, combination therapies
2027	~$1.2-$1.5 billion	~20-25%	Market maturity, pipeline developments

---

8. Key Takeaways

• Market prospects for WELIREG are positive, driven by increasing FGFR testing adoption, regulatory support, and expanding indications.
• Revenue growth is expected to be robust in the coming years, with strategic focus on pipeline development and geographic expansion.
• Competitive landscape remains intense, emphasizing the importance of differentiated efficacy, safety, and testing integration.
• Cost management and payer engagement are critical for sustaining profitability amid evolving reimbursement policies.
• Monitoring pipeline developments and regulatory trends will be essential for long-term strategic positioning.

---

9. FAQs

Q1: What is the current approved indication for WELIREG?
A1: WELIREG is approved for adult patients with locally advanced or metastatic urothelial carcinoma harboring FGFR3 or FGFR2 genetic alterations after prior platinum-based chemotherapy.

Q2: What is the prevalence of FGFR alterations in urothelial carcinoma?
A2: FGFR alterations are present in approximately 15-20% of urothelial carcinoma cases, representing a significant subset of patients eligible for targeted therapy.

Q3: How does WELIREG compare to its competitors?
A3: WELIREG was the first FDA-approved FGFR inhibitor for urothelial carcinoma and maintains a competitive advantage due to its oral administration and validated biomarker specificity; however, emerging inhibitors like infigratinib and rogaratinib are progressing in late-phase trials.

Q4: What are the key factors influencing WELIREG’s market penetration?
A4: Key factors include the rate of biomarker testing adoption, regulatory approvals for earlier lines, payer reimbursement policies, and clinical outcomes efficacy.

Q5: What strategies could enhance WELIREG’s long-term market success?
A5: Strategies include expanding indications, forming diagnostic partnerships, investing in pipeline programs, optimizing pricing and reimbursement, and targeted geographic expansion.

---

References

1. U.S. Food and Drug Administration. (2022). FDA approves Erdafitinib for bladder cancer.
2. MarketWatch. (2023). Urothelial carcinoma market report.
3. ClinicalTrials.gov. (2023). Ongoing gefitinib combination therapies in urothelial carcinoma trials.
4. GlobalData. (2023). Oncology Pipeline Analysis: FGFR inhibitors.
5. The European Medicines Agency (EMA). Draft guidance on biomarker-driven therapy approvals.